(Q41670505)

English

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

scientific article published on 22 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 October 2017

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial (English)

1 reference

Europe PubMed Central

6 October 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Clifford J Bailey

1

1 reference

Europe PubMed Central

6 October 2017

author name string

E C Morales Villegas

2

1 reference

Europe PubMed Central

6 October 2017

V Woo

3

1 reference

Europe PubMed Central

6 October 2017

W Tang

4

1 reference

Europe PubMed Central

6 October 2017

A Ptaszynska

5

1 reference

Europe PubMed Central

6 October 2017

J F List

6

1 reference

Europe PubMed Central

6 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 November 2014

1 reference

Europe PubMed Central

6 October 2017

Diabetic Medicine

1 reference

Europe PubMed Central

6 October 2017

32

1 reference

Europe PubMed Central

6 October 2017

4

1 reference

Europe PubMed Central

6 October 2017

531-541

1 reference

Europe PubMed Central

6 October 2017

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Improving efficiency of inferences in randomized clinical trials using auxiliary covariates

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

1 reference

https://api.crossref.org/works/10.1111%2FDME.12624

21 January 2018

Identifiers

10.1111/DME.12624

1 reference

Europe PubMed Central

6 October 2017

1 reference

Europe PubMed Central

6 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41670505&oldid=1925695865"